Identify biological Alzheimer's disease using a novel nucleic acid-linked protein immunoassay.

ABSTRACT: Blood-based biomarkers have been revolutionizing the detection, diagnosis and screening of Alzheimer's disease. Specifically, phosphorylated-tau variants (p-tau₁₈₁, p-tau₂₁₇ and p-tau₂₃₁) are promising biomarkers for identifying Alzheimer's disease pathology. Antibody-based assays such as single molecule arrays immunoassays are powerful tools to investigate pathological changes indicated by blood-based biomarkers and have been studied extensively in the Alzheimer's disease research field. A novel proteomic technology-NUcleic acid Linked Immuno-Sandwich Assay (NULISA)-was developed to improve the sensitivity of traditional proximity ligation assays and offer a comprehensive outlook for 120 protein biomarkers in neurodegenerative diseases. Due to the relative

SUBMITTER: Wang YT 

PROVIDER: S-EPMC11753389 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature